Viatris Inc.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ZTS has a market cap of 68.1B. Regarding current trading prices, VTRS is priced at $9.35, while ZTS trades at $152.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ZTS's P/E ratio is 27.50. In terms of profitability, VTRS's ROE is -0.21%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, VTRS is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TAK has a market cap of 46.3B. Regarding current trading prices, VTRS is priced at $9.35, while TAK trades at $14.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TAK's P/E ratio is 63.70. In terms of profitability, VTRS's ROE is -0.21%, compared to TAK's ROE of +0.04%. Regarding short-term risk, VTRS is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, HLN has a market cap of 44.3B. Regarding current trading prices, VTRS is priced at $9.35, while HLN trades at $9.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas HLN's P/E ratio is 23.48. In terms of profitability, VTRS's ROE is -0.21%, compared to HLN's ROE of +0.09%. Regarding short-term risk, VTRS is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TEVA has a market cap of 18.8B. Regarding current trading prices, VTRS is priced at $9.35, while TEVA trades at $16.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TEVA's P/E ratio is -14.22. In terms of profitability, VTRS's ROE is -0.21%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, VTRS is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, VTRS is priced at $9.35, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ITCI's P/E ratio is -180.64. In terms of profitability, VTRS's ROE is -0.21%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, VTRS is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, NBIX has a market cap of 13B. Regarding current trading prices, VTRS is priced at $9.35, while NBIX trades at $131.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas NBIX's P/E ratio is 44.62. In terms of profitability, VTRS's ROE is -0.21%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, VTRS is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, RDY has a market cap of 12.2B. Regarding current trading prices, VTRS is priced at $9.35, while RDY trades at $14.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas RDY's P/E ratio is 18.62. In terms of profitability, VTRS's ROE is -0.21%, compared to RDY's ROE of +0.18%. Regarding short-term risk, VTRS is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, VTRS is priced at $9.35, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CTLT's P/E ratio is -27.84. In terms of profitability, VTRS's ROE is -0.21%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, VTRS is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, RGC has a market cap of 7.5B. Regarding current trading prices, VTRS is priced at $9.35, while RGC trades at $15.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas RGC's P/E ratio is -1518.00. In terms of profitability, VTRS's ROE is -0.21%, compared to RGC's ROE of -0.50%. Regarding short-term risk, VTRS is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ELAN has a market cap of 7.3B. Regarding current trading prices, VTRS is priced at $9.35, while ELAN trades at $14.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ELAN's P/E ratio is 19.58. In terms of profitability, VTRS's ROE is -0.21%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, VTRS is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, LNTH has a market cap of 4.9B. Regarding current trading prices, VTRS is priced at $9.35, while LNTH trades at $70.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas LNTH's P/E ratio is 20.21. In terms of profitability, VTRS's ROE is -0.21%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, VTRS is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PRGO has a market cap of 3.9B. Regarding current trading prices, VTRS is priced at $9.35, while PRGO trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PRGO's P/E ratio is -23.42. In terms of profitability, VTRS's ROE is -0.21%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, VTRS is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AMRX has a market cap of 3.7B. Regarding current trading prices, VTRS is priced at $9.35, while AMRX trades at $8.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AMRX's P/E ratio is -200.13. In terms of profitability, VTRS's ROE is -0.21%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, VTRS is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, HCM has a market cap of 3.1B. Regarding current trading prices, VTRS is priced at $9.35, while HCM trades at $17.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas HCM's P/E ratio is 88.90. In terms of profitability, VTRS's ROE is -0.21%, compared to HCM's ROE of +0.05%. Regarding short-term risk, VTRS is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, VTRS is priced at $9.35, while ALVOW trades at $1.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ALVOW's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.21%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, VTRS is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, VTRS is priced at $9.35, while ALVO trades at $9.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ALVO's P/E ratio is 24.78. In terms of profitability, VTRS's ROE is -0.21%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, VTRS is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, VTRS is priced at $9.35, while BHC trades at $6.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas BHC's P/E ratio is -56.46. In terms of profitability, VTRS's ROE is -0.21%, compared to BHC's ROE of +0.05%. Regarding short-term risk, VTRS is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, VTRS is priced at $9.35, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas DCPH's P/E ratio is -11.58. In terms of profitability, VTRS's ROE is -0.21%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, VTRS is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, BGM has a market cap of 2.2B. Regarding current trading prices, VTRS is priced at $9.35, while BGM trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas BGM's P/E ratio is -54.75. In terms of profitability, VTRS's ROE is -0.21%, compared to BGM's ROE of -0.03%. Regarding short-term risk, VTRS is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, INDV has a market cap of 2.1B. Regarding current trading prices, VTRS is priced at $9.35, while INDV trades at $16.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas INDV's P/E ratio is -336.20. In terms of profitability, VTRS's ROE is -0.21%, compared to INDV's ROE of -0.01%. Regarding short-term risk, VTRS is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, VTRS is priced at $9.35, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EMBCV's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.21%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, VTRS is priced at $9.35, while SUPN trades at $32.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SUPN's P/E ratio is 29.60. In terms of profitability, VTRS's ROE is -0.21%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, VTRS is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, VTRS is priced at $9.35, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TARO's P/E ratio is 30.05. In terms of profitability, VTRS's ROE is -0.21%, compared to TARO's ROE of +0.02%. Regarding short-term risk, VTRS is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, VTRS is priced at $9.35, while ANIP trades at $66.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ANIP's P/E ratio is -56.58. In terms of profitability, VTRS's ROE is -0.21%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, VTRS is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, VTRS is priced at $9.35, while EVO trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EVO's P/E ratio is -5.96. In terms of profitability, VTRS's ROE is -0.21%, compared to EVO's ROE of -0.22%. Regarding short-term risk, VTRS is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, VTRS is priced at $9.35, while HROW trades at $37.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas HROW's P/E ratio is -61.11. In terms of profitability, VTRS's ROE is -0.21%, compared to HROW's ROE of -0.36%. Regarding short-term risk, VTRS is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, VTRS is priced at $9.35, while DVAX trades at $11.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas DVAX's P/E ratio is -22.32. In terms of profitability, VTRS's ROE is -0.21%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, VTRS is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, VTRS is priced at $9.35, while FLXN trades at $25.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas FLXN's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.21%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, VTRS is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, VTRS is priced at $9.35, while PAHC trades at $29.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PAHC's P/E ratio is 37.65. In terms of profitability, VTRS's ROE is -0.21%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, VTRS is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, VTRS is priced at $9.35, while AVDL trades at $11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AVDL's P/E ratio is -43.25. In terms of profitability, VTRS's ROE is -0.21%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, VTRS is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, VTRS is priced at $9.35, while AMPH trades at $22.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AMPH's P/E ratio is 8.16. In terms of profitability, VTRS's ROE is -0.21%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, VTRS is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, COLL has a market cap of 1B. Regarding current trading prices, VTRS is priced at $9.35, while COLL trades at $32.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas COLL's P/E ratio is 26.34. In terms of profitability, VTRS's ROE is -0.21%, compared to COLL's ROE of +0.19%. Regarding short-term risk, VTRS is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, VTRS is priced at $9.35, while PCRX trades at $21.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PCRX's P/E ratio is -9.74. In terms of profitability, VTRS's ROE is -0.21%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, VTRS is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, VTRS is priced at $9.35, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PETQ's P/E ratio is 83.73. In terms of profitability, VTRS's ROE is -0.21%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, VTRS is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CRON has a market cap of 797.8M. Regarding current trading prices, VTRS is priced at $9.35, while CRON trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CRON's P/E ratio is 14.79. In terms of profitability, VTRS's ROE is -0.21%, compared to CRON's ROE of +0.05%. Regarding short-term risk, VTRS is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TLRY has a market cap of 729.6M. Regarding current trading prices, VTRS is priced at $9.35, while TLRY trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TLRY's P/E ratio is -0.64. In terms of profitability, VTRS's ROE is -0.21%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, VTRS is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EMBC has a market cap of 665.1M. Regarding current trading prices, VTRS is priced at $9.35, while EMBC trades at $11.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EMBC's P/E ratio is 12.79. In terms of profitability, VTRS's ROE is -0.21%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EOLS has a market cap of 621.5M. Regarding current trading prices, VTRS is priced at $9.35, while EOLS trades at $9.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EOLS's P/E ratio is -10.83. In terms of profitability, VTRS's ROE is -0.21%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, VTRS is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ORGO has a market cap of 602.6M. Regarding current trading prices, VTRS is priced at $9.35, while ORGO trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ORGO's P/E ratio is -29.69. In terms of profitability, VTRS's ROE is -0.21%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, VTRS is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, VTRS is priced at $9.35, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas BDSI's P/E ratio is 6.82. In terms of profitability, VTRS's ROE is -0.21%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, VTRS is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SIGA has a market cap of 504.4M. Regarding current trading prices, VTRS is priced at $9.35, while SIGA trades at $7.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SIGA's P/E ratio is 10.54. In terms of profitability, VTRS's ROE is -0.21%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, VTRS is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, KMDA has a market cap of 447.4M. Regarding current trading prices, VTRS is priced at $9.35, while KMDA trades at $7.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas KMDA's P/E ratio is 27.79. In terms of profitability, VTRS's ROE is -0.21%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, VTRS is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AQST has a market cap of 417.7M. Regarding current trading prices, VTRS is priced at $9.35, while AQST trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AQST's P/E ratio is -7.25. In terms of profitability, VTRS's ROE is -0.21%, compared to AQST's ROE of +1.07%. Regarding short-term risk, VTRS is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EBS has a market cap of 405.5M. Regarding current trading prices, VTRS is priced at $9.35, while EBS trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EBS's P/E ratio is -2.90. In terms of profitability, VTRS's ROE is -0.21%, compared to EBS's ROE of -0.27%. Regarding short-term risk, VTRS is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SNDL has a market cap of 396.3M. Regarding current trading prices, VTRS is priced at $9.35, while SNDL trades at $1.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SNDL's P/E ratio is -5.13. In terms of profitability, VTRS's ROE is -0.21%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, VTRS is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, VTRS is priced at $9.35, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ALIM's P/E ratio is 5.28. In terms of profitability, VTRS's ROE is -0.21%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, VTRS is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ESPR has a market cap of 295.3M. Regarding current trading prices, VTRS is priced at $9.35, while ESPR trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ESPR's P/E ratio is -1.75. In terms of profitability, VTRS's ROE is -0.21%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, VTRS is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TKNO has a market cap of 276.3M. Regarding current trading prices, VTRS is priced at $9.35, while TKNO trades at $5.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TKNO's P/E ratio is -11.24. In terms of profitability, VTRS's ROE is -0.21%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, VTRS is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, LFCR has a market cap of 272.1M. Regarding current trading prices, VTRS is priced at $9.35, while LFCR trades at $7.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas LFCR's P/E ratio is -5.00. In terms of profitability, VTRS's ROE is -0.21%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, VTRS is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ACB has a market cap of 270.5M. Regarding current trading prices, VTRS is priced at $9.35, while ACB trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ACB's P/E ratio is 21.86. In terms of profitability, VTRS's ROE is -0.21%, compared to ACB's ROE of +0.00%. Regarding short-term risk, VTRS is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, VTRS is priced at $9.35, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas LNDC's P/E ratio is -4.04. In terms of profitability, VTRS's ROE is -0.21%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, VTRS is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ZYBT has a market cap of 263M. Regarding current trading prices, VTRS is priced at $9.35, while ZYBT trades at $5.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ZYBT's P/E ratio is 185.00. In terms of profitability, VTRS's ROE is -0.21%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, VTRS is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CGC has a market cap of 230.5M. Regarding current trading prices, VTRS is priced at $9.35, while CGC trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CGC's P/E ratio is -0.27. In terms of profitability, VTRS's ROE is -0.21%, compared to CGC's ROE of -1.13%. Regarding short-term risk, VTRS is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, VTRS is priced at $9.35, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TYHT's P/E ratio is -1.61. In terms of profitability, VTRS's ROE is -0.21%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, VTRS is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, OGI has a market cap of 203.5M. Regarding current trading prices, VTRS is priced at $9.35, while OGI trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas OGI's P/E ratio is 11.69. In terms of profitability, VTRS's ROE is -0.21%, compared to OGI's ROE of +0.05%. Regarding short-term risk, VTRS is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SXTC has a market cap of 188M. Regarding current trading prices, VTRS is priced at $9.35, while SXTC trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SXTC's P/E ratio is 0.01. In terms of profitability, VTRS's ROE is -0.21%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, VTRS is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, DERM has a market cap of 179M. Regarding current trading prices, VTRS is priced at $9.35, while DERM trades at $7.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas DERM's P/E ratio is -20.77. In terms of profitability, VTRS's ROE is -0.21%, compared to DERM's ROE of -0.52%. Regarding short-term risk, VTRS is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, VTRS is priced at $9.35, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas REPH's P/E ratio is -8.04. In terms of profitability, VTRS's ROE is -0.21%, compared to REPH's ROE of -0.22%. Regarding short-term risk, VTRS is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, BIOA has a market cap of 168.5M. Regarding current trading prices, VTRS is priced at $9.35, while BIOA trades at $4.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas BIOA's P/E ratio is -2.37. In terms of profitability, VTRS's ROE is -0.21%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, VTRS is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, IXHL has a market cap of 152.7M. Regarding current trading prices, VTRS is priced at $9.35, while IXHL trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas IXHL's P/E ratio is -1.33. In terms of profitability, VTRS's ROE is -0.21%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, VTRS is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, THTX has a market cap of 144.8M. Regarding current trading prices, VTRS is priced at $9.35, while THTX trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas THTX's P/E ratio is -16.58. In terms of profitability, VTRS's ROE is -0.21%, compared to THTX's ROE of +0.38%. Regarding short-term risk, VTRS is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, IRWD has a market cap of 132.6M. Regarding current trading prices, VTRS is priced at $9.35, while IRWD trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas IRWD's P/E ratio is -4.31. In terms of profitability, VTRS's ROE is -0.21%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, VTRS is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, VTRS is priced at $9.35, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SCTL's P/E ratio is -7.86. In terms of profitability, VTRS's ROE is -0.21%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, VTRS is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CRDL has a market cap of 115.7M. Regarding current trading prices, VTRS is priced at $9.35, while CRDL trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CRDL's P/E ratio is -4.12. In terms of profitability, VTRS's ROE is -0.21%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, VTRS is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, VTRS is priced at $9.35, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PROC's P/E ratio is 1.53. In terms of profitability, VTRS's ROE is -0.21%, compared to PROC's ROE of -2.22%. Regarding short-term risk, VTRS is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, VTRS is priced at $9.35, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas OPTN's P/E ratio is -4.42. In terms of profitability, VTRS's ROE is -0.21%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, VTRS is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, VTRS is priced at $9.35, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ZOM's P/E ratio is -1.62. In terms of profitability, VTRS's ROE is -0.21%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, VTRS is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, VTRS is priced at $9.35, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas GRVI's P/E ratio is 26.05. In terms of profitability, VTRS's ROE is -0.21%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, VTRS is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, INCR has a market cap of 84.5M. Regarding current trading prices, VTRS is priced at $9.35, while INCR trades at $1.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas INCR's P/E ratio is -3.52. In terms of profitability, VTRS's ROE is -0.21%, compared to INCR's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, QNTM has a market cap of 81.6M. Regarding current trading prices, VTRS is priced at $9.35, while QNTM trades at $23.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas QNTM's P/E ratio is -1.80. In terms of profitability, VTRS's ROE is -0.21%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, VTRS is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ASRT has a market cap of 71.8M. Regarding current trading prices, VTRS is priced at $9.35, while ASRT trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ASRT's P/E ratio is -2.34. In terms of profitability, VTRS's ROE is -0.21%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, VTRS is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, VTRS is priced at $9.35, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, VTRS's ROE is -0.21%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, VTRS is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, VTRS is priced at $9.35, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SSIC's P/E ratio is 11.93. In terms of profitability, VTRS's ROE is -0.21%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, VTRS is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, VTRS is priced at $9.35, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas VLNS's P/E ratio is -1.03. In terms of profitability, VTRS's ROE is -0.21%, compared to VLNS's ROE of N/A. Regarding short-term risk, VTRS is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CPIX has a market cap of 50.3M. Regarding current trading prices, VTRS is priced at $9.35, while CPIX trades at $3.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CPIX's P/E ratio is -14.00. In terms of profitability, VTRS's ROE is -0.21%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, VTRS is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, VTRS is priced at $9.35, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas JUPW's P/E ratio is -2.41. In terms of profitability, VTRS's ROE is -0.21%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, VTRS is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, KALA has a market cap of 45.2M. Regarding current trading prices, VTRS is priced at $9.35, while KALA trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas KALA's P/E ratio is -0.95. In terms of profitability, VTRS's ROE is -0.21%, compared to KALA's ROE of -3.69%. Regarding short-term risk, VTRS is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, EGRX has a market cap of 40.8M. Regarding current trading prices, VTRS is priced at $9.35, while EGRX trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas EGRX's P/E ratio is 3.71. In terms of profitability, VTRS's ROE is -0.21%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, VTRS is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, VTRS is priced at $9.35, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas QLI's P/E ratio is -4.92. In terms of profitability, VTRS's ROE is -0.21%, compared to QLI's ROE of -0.16%. Regarding short-term risk, VTRS is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, RMTI has a market cap of 38.3M. Regarding current trading prices, VTRS is priced at $9.35, while RMTI trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas RMTI's P/E ratio is -112.00. In terms of profitability, VTRS's ROE is -0.21%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, VTRS is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, VTRS is priced at $9.35, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas HEXO's P/E ratio is -0.26. In terms of profitability, VTRS's ROE is -0.21%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, VTRS is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SCYX has a market cap of 28.8M. Regarding current trading prices, VTRS is priced at $9.35, while SCYX trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SCYX's P/E ratio is -1.32. In terms of profitability, VTRS's ROE is -0.21%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, VTRS is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, VTRS is priced at $9.35, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas CYTH's P/E ratio is -0.80. In terms of profitability, VTRS's ROE is -0.21%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, VTRS is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, GELS has a market cap of 18.8M. Regarding current trading prices, VTRS is priced at $9.35, while GELS trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas GELS's P/E ratio is -5.34. In terms of profitability, VTRS's ROE is -0.21%, compared to GELS's ROE of -0.07%. Regarding short-term risk, VTRS is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, DRRX has a market cap of 18.2M. Regarding current trading prices, VTRS is priced at $9.35, while DRRX trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas DRRX's P/E ratio is -1.22. In terms of profitability, VTRS's ROE is -0.21%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, VTRS is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, PRPH has a market cap of 17.5M. Regarding current trading prices, VTRS is priced at $9.35, while PRPH trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas PRPH's P/E ratio is -0.19. In terms of profitability, VTRS's ROE is -0.21%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, VTRS is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, COSM has a market cap of 17.2M. Regarding current trading prices, VTRS is priced at $9.35, while COSM trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas COSM's P/E ratio is -0.54. In terms of profitability, VTRS's ROE is -0.21%, compared to COSM's ROE of -0.51%. Regarding short-term risk, VTRS is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AYTU has a market cap of 16.3M. Regarding current trading prices, VTRS is priced at $9.35, while AYTU trades at $2.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AYTU's P/E ratio is -1.78. In terms of profitability, VTRS's ROE is -0.21%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, VTRS is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, VTRS is priced at $9.35, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas ACRX's P/E ratio is -0.31. In terms of profitability, VTRS's ROE is -0.21%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, VTRS is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, FLGC has a market cap of 13.8M. Regarding current trading prices, VTRS is priced at $9.35, while FLGC trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas FLGC's P/E ratio is -0.64. In terms of profitability, VTRS's ROE is -0.21%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, VTRS is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TXMD has a market cap of 13.2M. Regarding current trading prices, VTRS is priced at $9.35, while TXMD trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TXMD's P/E ratio is -6.00. In terms of profitability, VTRS's ROE is -0.21%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, VTRS is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, BFRI has a market cap of 11.2M. Regarding current trading prices, VTRS is priced at $9.35, while BFRI trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas BFRI's P/E ratio is -1.36. In terms of profitability, VTRS's ROE is -0.21%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, VTRS is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, VTRS is priced at $9.35, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas AGRX's P/E ratio is -0.89. In terms of profitability, VTRS's ROE is -0.21%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, VTRS is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, TLPH has a market cap of 8.9M. Regarding current trading prices, VTRS is priced at $9.35, while TLPH trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas TLPH's P/E ratio is -0.99. In terms of profitability, VTRS's ROE is -0.21%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, VTRS is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, IMCC has a market cap of 8.9M. Regarding current trading prices, VTRS is priced at $9.35, while IMCC trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas IMCC's P/E ratio is -2.08. In terms of profitability, VTRS's ROE is -0.21%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, VTRS is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, YCBD has a market cap of 8.2M. Regarding current trading prices, VTRS is priced at $9.35, while YCBD trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas YCBD's P/E ratio is 0.01. In terms of profitability, VTRS's ROE is -0.21%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, VTRS is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, VTRS is priced at $9.35, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas NLTX's P/E ratio is -0.28. In terms of profitability, VTRS's ROE is -0.21%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, VTRS is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, SISI has a market cap of 7.5M. Regarding current trading prices, VTRS is priced at $9.35, while SISI trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas SISI's P/E ratio is N/A. In terms of profitability, VTRS's ROE is -0.21%, compared to SISI's ROE of -1.41%. Regarding short-term risk, VTRS is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.

VTRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VTRS stands at 11B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, VTRS is priced at $9.35, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VTRS currently has a P/E ratio of -2.94, whereas LCI's P/E ratio is -0.04. In terms of profitability, VTRS's ROE is -0.21%, compared to LCI's ROE of +1.66%. Regarding short-term risk, VTRS is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for VTRS.